Autoimmune myositis disease detection kit and detection method

By using fluorescently encoded magnetic microspheres and fluorescently labeled secondary antibody solutions, the low efficiency and cross-contamination problems of multi-item myositis antibody detection in existing technologies have been solved, achieving efficient and sensitive detection of 17 myositis antibody spectrum items, supporting clinical diagnosis and treatment.

CN117470819BActive Publication Date: 2026-11-10SHENZHEN YHLO BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311223860.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-21
Publication Date
2026-11-10
Estimated Expiration
2043-09-21

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This application relates to a diagnostic kit for autoimmune myositis and a detection method thereof. The kit comprises: a suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen, respectively, and a fluorescently labeled secondary antibody solution; wherein the JO-1 antigen includes antigen A and antigen B, wherein antigen A is a natural antigen and antigen B is a recombinant antigen.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of biotechnology, and more specifically, to a diagnostic kit and method for autoimmune myositis. Background Technology

[0002] Autoimmune myositis is a disease with an unclear pathogenesis and is associated with other diseases. Accurate diagnosis is difficult in the early stages clinically; therefore, timely and accurate detection of autoimmune myositis antibodies is of great significance for disease diagnosis and further prognosis.

[0003] Idiopathic inflammatory myopathy (IIM) is a heterogeneous immune disease characterized primarily by skeletal muscle involvement. It involves various autoantibodies and can be classified into several clinical subtypes based on the specific antibodies present, including polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (IBM), immune-mediated necrotizing myopathy (IMNM), juvenile idiopathic myositis (JIM), and antisynthetase syndrome (ASS). Autoantibodies present only in IIM are called myositis-specific autoantibodies (MSA), while some antibodies are also found in other diseases and are called myositis-associated autoantibodies (MAA).

[0004] Currently, the commonly used methods for myositis detection, such as enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay, are both single antibody detection methods. As patients' requirements become more demanding and the number of patients requiring testing increases, while hospital resources are limited, single myositis antibody detection cannot meet the actual needs. Therefore, the detection of multiple autoimmune myositis antibodies is becoming increasingly urgent in the treatment of autoimmune myositis disease.

[0005] Immunoblotting, used for myositis antibody profiling, allows for the simultaneous detection of multiple antibodies. However, due to limitations in its detection principle, it is time-consuming, requires large sample volumes, and is prone to cross-contamination leading to poor reagent repeatability. Therefore, there is an urgent need for a technology and product that can efficiently and simultaneously detect multiple autoimmune myositis antibodies. Summary of the Invention

[0006] Based on this, this application provides a detection kit and method for autoimmune myositis.

[0007] Specifically, this is achieved through the following technical solution:

[0008] This application provides a detection kit for autoimmune myositis, the kit comprising: a mixture of fluorescently encoded magnetic microspheres coated with antigens JO-1, OJ, EJ, PL-7, PL-12, SRP, HMGCR, Mi-2α, Mi-2β, TIF1γ, NXP2, SAE1, MDA5, SSA / Ro52kD, Ku, PM-Scl 75, and PM-Scl 100, respectively, and a fluorescently labeled secondary antibody solution; wherein the JO-1 antigen comprises antigen A and antigen B, wherein antigen A is a natural antigen and antigen B is a recombinant antigen.

[0009] In some embodiments, the mass ratio of antigen A to antigen B coated on fluorescently encoded magnetic microspheres coated with JO-1 antigen is (1~3):1.

[0010] In some embodiments, antigen A and antigen B have the same amino acid sequence, as shown in SEQ ID NO.1.

[0011] In some embodiments, the fluorescently labeled secondary antibody is an anti-human IgG antibody, which is selected from at least one of goat anti-human IgG antibody or mouse anti-human IgG antibody.

[0012] In some embodiments, the fluorescent substance includes at least one of phycoerythrin, phycoerythrin-Cy7 complex dye, fluorescein isothiocyanate, polydoxylin-chlorophyll-protein complex, and allophycocyanin.

[0013] In some embodiments, the kit also includes a secondary antibody diluent.

[0014] In some embodiments, the secondary antibody dilution solution comprises a phosphate buffer containing bovine serum albumin and an inhibitor.

[0015] In some embodiments, the blocking agent includes an active blocking agent and a passive blocking agent, wherein the active blocking agent is selected from at least one of human anti-mouse antibody HAMA blocking agent, heterophile antibody blocking agent and rheumatoid factor RF blocking agent; and the passive blocking agent is selected from at least one of mouse IgG, sheep IgG, goat IgG and bovine IgG.

[0016] In some embodiments, the kit further includes a sample diluent; the sample diluent includes at least one of phosphate buffer containing protein-containing serum and Tris buffer.

[0017] Compared with traditional technologies, this application can simultaneously quantify 17 antibodies in the autoimmune myositis spectrum, with low sample volume, high sensitivity, and convenient and easy-to-automate operation. Among them, JO-1 uses a mixed coating method of natural antigens and recombinant antigens with different protein conformations to improve detection efficiency, providing a reference for the screening, diagnosis and treatment of autoimmune myositis in clinical practice.

[0018] Another aspect of this application provides a method for detecting autoimmune myositis, comprising the following steps: taking a sample to be tested, performing an antigen-antibody reaction using the above-described kit, and analyzing the detection results by detecting the fluorescence intensity of the reaction product.

[0019] The method described in this application for detecting autoimmune myositis allows for the simultaneous quantitative detection of 17 antibodies in the autoimmune myositis spectrum using the same sample. Detailed Implementation

[0020] The following detailed description of a diagnostic kit for autoimmune myositis, based on specific embodiments, further illustrates this application. This application can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of the disclosure of this application.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

[0022] As used herein, the terms “and / or,” “or / and,” and “and / or” may include any one of two or more of the related listed items, as well as any and all combinations of the related listed items, including any two related listed items, any more related listed items, or a combination of all the related listed items.

[0023] In this application, numerical intervals (i.e., numerical ranges) are involved. Unless otherwise specified, the selected numerical distributions within the aforementioned numerical intervals are considered continuous and include the two endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. In this document, this is equivalent to directly listing every integer. For example, if t is an integer selected from 1 to 10, it means that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Furthermore, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0024] Unless otherwise specified, the temperature parameters in this application are permitted to be either constant-temperature treatment or variations within a certain temperature range. It should be understood that the constant-temperature treatment allows temperature fluctuations within the precision range of the instrument control, such as ±5℃, ±4℃, ±3℃, ±2℃, or ±1℃.

[0025] The spectrum of autoimmune myositis generally includes IgG antibodies in human serum, such as JO-1, OJ, EJ, PL-7, PL-12, SRP, HMGCR, Mi-2α, Mi-2β, TIF1γ, NXP2, SAE1, MDA5, SSA / Ro52kD, Ku, PM-Scl 75, and PM-Scl 100. MSAs include antibodies against melanoma differentiation-associated gene (MDA)-5, transcriptional intermediary factor (TIF)-1γ, nuclear matrix protein (NXP)-2, histidyl-tRNA synthetase (JO-1), small ubiquitin-like modifier activating enzyme (SAE), and nucleosome remodeling and histone deacetylase protein complex (Mi-2). Detection of these myositis-specific antibodies is helpful for the diagnosis, clinical classification, treatment, and prognostic assessment of IIM.

[0026] One embodiment of this application provides a detection kit for autoimmune myositis. The kit includes: a suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen, respectively, and a secondary antibody solution labeled with fluorescent substances; the JO-1 antigen includes antigen A and antigen B, wherein antigen A is a natural antigen and antigen B is a recombinant antigen.

[0027] Compared with traditional technologies, this application can simultaneously quantify 17 antibodies in the autoimmune myositis spectrum, with low sample volume, high sensitivity, and convenient and easy-to-automate operation. Among them, JO-1 uses a mixed coating method of natural antigens and recombinant antigens with different protein conformations to improve detection efficiency, providing a reference for the screening, diagnosis and treatment of autoimmune myositis in clinical practice.

[0028] In some embodiments, the mass ratio of antigen A to antigen B coated on the fluorescently encoded magnetic microspheres coated with JO-1 antigen is (1~3):1.

[0029] In some embodiments, antigen A and antigen B have the same amino acid sequence, as shown in SEQ ID NO.1.

[0030] Specifically, the amino acid sequence shown in SEQ ID NO 1 is: MAERAALEELVKLQGERVRGLKQQKASAELIEEEVAKLLKLKAQLGPDESKQKFVLKTPKGTRDYSPRQMAVREKVFDVIIRCFKRHGAEVIDTPVFELKETLMGKYGEDSKLIYDLKDQGGELLSLRYDLTVPFARYLAMNKLTNIKRYHIAKVYRRDNPAMTRGRYREFYQCDFDIAGNFDPMIPDAECLKIMCEILSSLQIGDFLVKVNDRRILDGMFAICGVSDSKFRTICSSVDKLDKVSWEEV KNEMVGEKGLAPEVADRIGDYVQQHGGVSLVEQLLQDPKLSQNKQALEGLGDLKLLFEYLTLFGIDDKISFDLSLARGLDYYTGVIYEAVLLQTPAQAGEEPLGVGSVAAGGRYDGLVGMFDPKGRKVPC VGLSIGVERIFSIVEQRLEALEEKIRTTETQVLVASAQKKLLEERLKLVSELWDAGIKAELLYKKNPKLLNQLQYCEEAGIPLVAIIGEQELKDGVIKLRSVTSREEVDVRREDLVEEIKRRTGQPLCIC.

[0031] Natural antigens are antigens extracted and purified from animal tissues or microorganisms in vitro. Recombinant antigens are antigens obtained by transferring an antigen gene-linking vector into prokaryotic or eukaryotic cells, followed by in vitro recombination expression and purification. Typically, the gene sequence, amino acid composition, and molecular weight of recombinant antigens are identical to those of natural antigens. However, the determinants of different types of antigens A and B may be linear and continuous, determined by primary structure, or discontinuous, determined by tertiary structure. Linear epitopes retain immunogenicity even after protein denaturation; conformational epitopes, on the other hand, only possess immunogenicity when their spatial structure remains intact. The conformation and modification of recombinant antigens differ from those of natural antigens. Natural antigens possess natural sequences and a comprehensive range of antigenic epitopes; recombinant antigens can have their sequences artificially designed, highlighting key epitopes, and can be produced in large, controllable quantities. They are also easy to purify and can be tagged for easier detection.

[0032] In some embodiments, antigen A is a natural antigen derived from the thymus of a calf, and antigen B is a recombinant antigen expressed by insect cells.

[0033] In some embodiments, the coating ratio of JO-1 antigen to fluorescently encoded magnetic microspheres in the above suspension is: 10 μg to 200 μg of antigen coating 1 × 1026 A magnetic fluorescently encoded microsphere.

[0034] In some of these embodiments, the fluorescently labeled secondary antibody is an anti-human IgG antibody.

[0035] In some of these embodiments, the anti-human IgG antibody is selected from at least one of sheep anti-human IgG antibody or mouse anti-human IgG antibody.

[0036] In some embodiments, the fluorescent material includes fluorescein, fluorescent protein, and other substances that can fluoresce.

[0037] In some embodiments, the fluorescent material includes at least one of phycoerythrin (PE), phycoerythrin PE-Cy7 complex dye, fluorescein isothiocyanate (FITC), polydoxylin-chlorophyll-protein complex (PerCP), and allophycocyanin (APC).

[0038] In some embodiments, the kit also includes a secondary antibody diluent.

[0039] In some embodiments, the secondary antibody dilution solution includes a phosphate buffer containing bovine serum albumin and an inhibitor.

[0040] In one embodiment, the mass percentage of the blocking agent is 0.1% to 10% based on the total mass of the fluorescently labeled secondary antibody dilution.

[0041] In some embodiments, the blocking agent includes an active blocking agent and a passive blocking agent, wherein the active blocking agent is selected from at least one of human anti-mouse antibody (HAMA) blocking agents, heterophile antibody blocking agents, and rheumatoid factor (RF) blocking agents.

[0042] In one embodiment, the passive blocker is selected from at least one of mouse IgG, sheep IgG, goat IgG, and bovine IgG.

[0043] In some embodiments, the kit also includes a sample diluent, which includes at least one of phosphate buffer or Tris buffer containing protein serum.

[0044] In some embodiments, the suspension also includes serum proteins, surfactants, macromolecular polymers, sugars or alcohols, and preservatives.

[0045] It is understandable that serum proteins, surfactants, macromolecular polymers, sugars or alcohols, and preservatives are added to the suspension to ensure the stability of the fluorescently encoded magnetic microsphere suspension.

[0046] This application also provides a method for detecting autoimmune myositis. In a specific example, the detection method includes the following steps S10 and S20.

[0047] Step S10: Obtain the sample to be tested, and dilute the sample to be tested with sample diluent to obtain a diluted sample.

[0048] In one embodiment, in step S10, the sample to be tested is selected from serum or plasma samples.

[0049] In one embodiment, the volume ratio of the sample diluent to the sample to be tested is (30~100):1.

[0050] Step S20: Take the diluted sample obtained in step S10, perform antigen-antibody reaction using the above-mentioned kit, and analyze the detection results by detecting the fluorescence intensity of the reaction product.

[0051] Specifically, in step S20, the reaction is carried out using the above-mentioned kit, and the steps of analyzing the detection results by detecting the fluorescence intensity of the reaction product include steps S21, S22, S23, and S24.

[0052] Step S21: The diluted sample obtained in step S10 is mixed with a suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen and PM-Scl 100 antigen respectively, to perform a specific antibody reaction. The microspheres are then magnetically separated and washed with microsphere washing solution to prepare a magnetic microsphere-antigen-specific IgG autoantibody complex.

[0053] In one embodiment, the volume ratio of the diluted sample to the suspension of fluorescently encoded magnetic microspheres is (0.5~1):1.

[0054] In one embodiment, the reaction temperature is 37±1℃.

[0055] In one embodiment, the reaction time is 15 min to 60 min.

[0056] Optionally, the method for preparing the suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen respectively includes steps a, b, c, d, and e.

[0057] Step a: Take 100μL~150μL of fluorescently encoded magnetic microsphere suspension (approximately 1.25*10^6 microspheres) into centrifuge tubes, place the centrifuge tubes on a magnetic rack for magnetic adsorption, separate and discard the supernatant; add 200μL~1000μL of microsphere washing solution for washing, repeat twice; resuspend the washed fluorescently encoded magnetic microspheres with 100μL~500μL of resuspension solution to obtain resuspension solution A.

[0058] Step b: Add activator to microsphere resuspension A to make the activator concentration 5 mg / mL, and react at room temperature in the dark for 10-60 min; add 200 μL~1000 μL of microsphere washing solution to wash, repeat twice; resuspend the washed fluorescently encoded magnetic microspheres with 100 μL~1000 μL of resuspension solution to obtain resuspension B.

[0059] Step c: Add the corresponding antigen to the microsphere resuspension B to make the antigen concentration 10-100 μg / mL, and react at room temperature in the dark for 1-12 h; add 200-1000 μL of microsphere blocking solution for washing, and repeat twice; resuspend the washed fluorescently encoded magnetic microspheres with 100-1000 μL of blocking solution to obtain resuspension C.

[0060] Step d: Add the cleaned fluorescently encoded magnetic microspheres to an equal volume of blocking solution and react at room temperature in the dark for 1-12 hours to carry out the blocking reaction. Then, perform magnetic separation and cleaning on the fluorescently encoded magnetic microspheres after the reaction.

[0061] Step e: Add the cleaned fluorescently encoded magnetic microspheres to the microsphere preservation solution for resuspending to obtain fluorescently encoded magnetic microsphere resuspension; add the fluorescently encoded magnetic microsphere resuspension coated with different antigens to the microsphere preservation solution, so that the number of each type of microsphere is between 2000 and 5000, to prepare a suspension of fluorescently encoded magnetic microspheres coated with different antigens.

[0062] Step S22: Mix the magnetic microsphere-antigen-specific IgG autoantibody complex obtained in step S21 with a fluorescently labeled secondary antibody solution to detect the antibody reaction. Perform magnetic separation and cleaning with microsphere washing solution to prepare the magnetic microsphere-antigen-specific IgG autoantibody-fluorescently labeled secondary antibody complex.

[0063] In one embodiment, the secondary antibody solution is a goat anti-human IgG antibody with a concentration of 1 μg / mL to 20 μg / mL.

[0064] Step S23: Add magnetic washing solution to the magnetic microsphere-antigen-specific IgG autoantibody-fluorescently labeled secondary antibody complex for resuspending to obtain the resuspended magnetic microsphere-antigen-specific IgG autoantibody-fluorescently labeled secondary antibody complex.

[0065] Step S24: Load the resuspended magnetic microsphere-antigen-specific IgG autoantibody-fluorescently labeled secondary antibody complex for detection, obtain the fluorescence signal value, and analyze the detection results.

[0066] Using the kit for detecting autoimmune myositis described in this application, the same sample can be used to simultaneously and quantitatively detect 17 antibodies in the autoimmune myositis spectrum, providing a reference for the screening and treatment of autoimmune myositis in clinical practice.

[0067] To make the objectives, technical solutions, and advantages of this application clearer and more concise, the following specific embodiments are used for illustration, but this application is by no means limited to these embodiments. The embodiments described below are merely preferred embodiments of this application and can be used to describe this application, but should not be construed as limiting the scope of this application. It should be noted that any modifications, equivalent substitutions, and improvements made within the spirit and principles of this application should be included within the protection scope of this application.

[0068] To better illustrate this application, the following embodiments further explain its content. Specific embodiments are provided below. Unless otherwise specified, the reagents and instruments used in the embodiments are conventionally selected in the art. Experimental methods not specifying specific conditions in the embodiments are typically implemented under conventional conditions, such as those described in literature, books, or methods recommended by reagent kit manufacturers. All reagents used in the embodiments are commercially available.

[0069] Example 1

[0070] 1. To provide a diagnostic kit for autoimmune myositis.

[0071] The kit includes a suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen, respectively; a fluorescently labeled secondary antibody solution; a sample diluent; and a fluorescently labeled secondary antibody diluent.

[0072] The JO-1 antigen includes: natural antigen A derived from the calf thymus and recombinant antigen B expressed by insect cells (Sf9); the amino acid sequences of antigen A and antigen B are shown in SEQ ID NO.1.

[0073] 2. Detection Principle

[0074] During the detection process, different myositis spectrum antigens are covalently cross-linked on the surface of magnetic microspheres with different fluorescent codes. The sample is first mixed with a suspension. Specific IgG antibodies in the sample recognize and bind to specific antigens on the surface of the fluorescently encoded magnetic microspheres, forming a magnetically encoded microsphere-antigen-specific IgG autoantibody complex. This complex is then separated using magnetic separation. Subsequently, a fluorescently labeled secondary antibody is added, ultimately forming a magnetic microsphere-antigen-specific IgG autoantibody-fluorescently labeled secondary antibody complex.

[0075] When detecting the complex, two laser beams are focused onto the coded microspheres. One beam determines the fluorescence code of the microsphere, identifying the analyte; the other beam measures the fluorescence intensity of the fluorescent substance on the microsphere, i.e., the fluorescence value, which is positively correlated with the concentration of the corresponding analyte in the sample. The concentration of IgG antibody for each analyte is obtained through calibration curves for each analyte.

[0076] 3. Preparation of suspension

[0077] 3.1 Pretreatment: Take 100 μL of fluorescently encoded magnetic microsphere suspension into 17 centrifuge tubes, place the 17 centrifuge tubes on a magnetic rack for magnetic adsorption, and discard the supernatant after separation; add 200 μL of microsphere washing solution to each tube for washing, repeat twice; resuspend the washed fluorescently encoded magnetic microspheres with 200 μL of resuspension solution to obtain 17 resuspensions A.

[0078] 3.2 Activation: Activator was added to each of the 17 microsphere resuspensions A to make the concentration of activator 5 mg / mL, and the reaction was carried out at room temperature in the dark for 30 min. Each microsphere was washed with 200 μL of microsphere washing solution, and the process was repeated twice. The washed fluorescently encoded magnetic microspheres were resuspended in 200 μL of resuspension solution to obtain 17 resuspensions B.

[0079] 3.3 Labeling: The corresponding antigen was added to each of the 17 microsphere resuspensions B to make the antigen concentration 20 μg / mL, and the reaction was carried out at room temperature in the dark for 2 h. Each microsphere was washed with 200 μL of microsphere blocking solution, and the process was repeated twice. The washed fluorescently encoded magnetic microspheres were resuspended with 200 μL of blocking solution to obtain 17 resuspensions C.

[0080] 3.4 Blocking: The cleaned fluorescently encoded magnetic microspheres were added to equal volumes of blocking solution and reacted at room temperature in the dark for 2 h to carry out the blocking reaction. The fluorescently encoded magnetic microspheres after the reaction were then magnetically separated and cleaned.

[0081] 3.5 Preservation: The cleaned fluorescently coded magnetic microspheres were resuspended in microsphere preservation solution to obtain 17 kinds of fluorescently coded magnetic microsphere resuspensions; the 17 kinds of fluorescently coded magnetic microsphere resuspensions were added to the microsphere preservation solution to make the number of each kind of microspheres 2000, which is the fluorescently coded magnetic microsphere suspension.

[0082] 4. Testing process

[0083] 4.1 Sample preparation: The test samples are derived from plasma collected from the hospital. The test samples are diluted with sample diluent at a ratio of 30:1 to obtain diluted samples.

[0084] 4.2 Specific antibody reaction: 30 μL of diluted sample was mixed with 50 μL of fluorescently encoded magnetic microsphere suspension and reacted at 37℃ for 15 min. Then, the sample was magnetically separated and washed twice with microsphere washing solution to obtain magnetic microsphere-antigen-specific IgG autoantibody complex.

[0085] 4.3 Detection of antibody reaction: 100 μL of phycoerythrin-labeled secondary antibody solution was added to the magnetic microsphere-antigen-specific IgG autoantibody complex. After reacting at 37℃ for 15 min, the complex was magnetically separated and washed twice with microsphere washing buffer to obtain the magnetic microsphere-antigen-specific IgG autoantibody-phycoerythrin-labeled secondary antibody complex. The phycoerythrin-labeled secondary antibody solution was goat anti-human IgG antibody with a final concentration of 10 μg / mL (the stock solution was purchased from Solarbio).

[0086] 4.4 Detection: 50 μL of magnetic washing buffer was added to the magnetic microsphere-antigen-specific IgG autoantibody-phycoerythrin-labeled secondary antibody complex for resuspending, resulting in a resuspended magnetic microsphere-antigen-specific IgG autoantibody-phycoerythrin-labeled secondary antibody complex. The resuspended magnetic microsphere-antigen-specific IgG autoantibody-phycoerythrin-labeled secondary antibody complex was detected and analyzed using flow cytometry.

[0087] Prepare a suspension of fluorescently encoded magnetic microspheres coated with JO-1 (both A and B) antigens, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen according to step 3. Detect the sample according to step 4. No blocking agent is added to the fluorescent secondary antibody. See Tables 1-2 for specific reagent types and formulations, and Tables 3-6 for specific test results.

[0088] Example 2:

[0089] Example 2 is basically the same as the method for detecting autoimmune myositis in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. Following step 3, a fluorescently encoded magnetic microsphere suspension coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen is prepared. The sample to be tested is then tested according to step 4, with two blocking agents added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 2, and specific test results are shown in Tables 5 and 6.

[0090] Example 3

[0091] Example 3 is basically the same as the method for detecting autoimmune myositis in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. Following step 3, a fluorescently encoded magnetic microsphere suspension coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen is prepared. The sample to be tested is then tested according to step 4, with two blocking agents added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 2, and specific test results are shown in Tables 5 and 6.

[0092] Example 4

[0093] Example 4 is basically the same as the method for detecting autoimmune myositis in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. Following step 3, a fluorescently encoded magnetic microsphere suspension coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen is prepared. The sample to be tested is then tested according to step 4, with two blocking agents added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 2, and specific test results are shown in Tables 5 and 6.

[0094] Example 5

[0095] Example 5 is basically the same as the method for detecting autoimmune myositis in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. Following step 3, a fluorescently encoded magnetic microsphere suspension coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen is prepared. The sample to be tested is then tested according to step 4, with two blocking agents added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 2, and specific test results are shown in Tables 5 and 6.

[0096] Example 6

[0097] Example 6 uses a method similar to Example 1 for detecting autoimmune myositis, the difference being the JO-1 antigen ratio. Following step 3, a fluorescently encoded magnetic microsphere suspension coated with JO-1 antigen (two types, A and B, in a mass ratio of 3:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared. The sample was then tested according to step 4. No blocking agent was added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and the specific test results are shown in Table 4.

[0098] Example 7

[0099] The method for detecting autoimmune myositis in Example 7 is basically the same as that in Example 1, except that the ratio of JO-1 antigen is different. A fluorescently encoded magnetic microsphere suspension coated with JO-1 antigen (two types, A and B, in a mass ratio of 1:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared according to step 3. The sample to be tested was then tested according to step 4. No blocking agent was added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and specific test results are shown in Table 4.

[0100] Comparative Example 1

[0101] The methods for detecting autoimmune myositis in Comparative Example 1 and Example 1 are basically the same, except that the types of JO-1 antigens are different. A suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen (A antigen), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared according to step 3. The samples to be tested were then tested according to step 4. No blocking agent was added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and specific test results are shown in Table 4.

[0102] Comparative Example 2

[0103] The method for detecting autoimmune myositis in Comparative Example 2 is basically the same as that in Example 1, except that the types of JO-1 antigens are different. A fluorescently encoded magnetic microsphere suspension coated with JO-1 antigen (B antigen), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared according to step 3. The samples to be tested were then tested according to step 4. No blocking agent was added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and specific test results are shown in Table 4.

[0104] Comparative Example 3

[0105] The method for detecting autoimmune myositis in Comparative Example 3 is basically the same as that in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. A suspension of fluorescently encoded magnetic microspheres coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared according to step 3. The samples to be tested were then tested according to step 4, with one active blocking agent added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and specific test results are shown in Tables 5 and 6.

[0106] Comparative Example 4

[0107] The method for detecting autoimmune myositis in Comparative Example 4 is basically the same as that in Example 1, except that a combination of blocking agents is added to the fluorescent secondary antibody. A fluorescently encoded magnetic microsphere suspension coated with JO-1 (two types, A and B, in a mass ratio of 2:1), OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl 100 antigen was prepared according to step 3. The samples to be tested were then tested according to step 4, with one passive blocking agent added to the fluorescent secondary antibody. Specific reagent types and formulations are shown in Table 1, and specific test results are shown in Tables 5 and 6.

[0108] Table 1 Different JO-1 antigen ratios

[0109]

[0110] Table 2 Different combinations of blocking agents

[0111]

[0112] Table 3. Concentration values ​​of corresponding antibodies detected after different antigens were coated onto fluorescently encoded magnetic microspheres.

[0113]

[0114] As shown in Table 3, microsphere reagents were prepared by coating different encoded microspheres with antigens JO-1, OJ, EJ, PL-7, PL-12, SRP, HMGCR, Mi-2α, Mi-2β, TIF1γ, NXP2, SAE1, MDA5, SSA / Ro52kD, Ku, PM-Scl 75, and PM-Scl 100. These reagents, combined with sample dilution buffer and fluorescent secondary antibody solution, yielded results for 17 different myositis parameters in a single test. This provides a reference for the screening, diagnosis, and treatment of autoimmune myositis in clinical practice. Autoimmune myositis is a disease with extremely complex pathogenesis and clinical manifestations. Although the combined detection of autoantibodies improves the sensitivity and accuracy of diagnosis, its definitive diagnosis requires not only the detection of autoantibodies but also the combined detection of clinical manifestations and other biochemical indicators.

[0115] Table 4 Comparison of JO-1 test results with clinical outcomes

[0116]

[0117] Based on the test results in Table 4, it can be seen that the comparison of the clinical concordance rate between the JO-1 mixed antigen (two types, A and B, with a mass ratio of 2:1) coating results and the clinical concordance rate is better than that between coating with A or B antigen alone. Preferably, comparing Examples 6 and 7 with Example 1, the test results of three different mass ratios of antigen A and antigen B show that the optimal mass ratio of antigen A to antigen B of 2:1 yields the best concordance rate.

[0118] Table 5 Comparison of PL-7 test results with clinical results

[0119]

[0120] Table 6 Comparison of RO-52 test results with clinical results

[0121]

[0122] As shown in Tables 5 and 6, the addition of an inhibitor to the fluorescent secondary antibody affects the results. Adding an inhibitor reduces false positives, but due to the complexity of interference in the samples, even with an inhibitor, not all interference can be completely eliminated, although the number of false positives can be reduced. Furthermore, the removal of false positives is more significant with a combination of two inhibitors than with a single inhibitor. The optimal combination of inhibitors varies for different sub-projects. For Ro 52, for example, the best combination is 1.00% goat IgG with 0.50% heterophile antibody inhibitor.

[0123] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0124] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A diagnostic kit for autoimmune myositis, characterized in that, The kit comprises: a suspension of fluorescently encoded magnetic microspheres coated with JO-1 antigen, OJ antigen, EJ antigen, PL-7 antigen, PL-12 antigen, SRP antigen, HMGCR antigen, Mi-2α antigen, Mi-2β antigen, TIF1γ antigen, NXP2 antigen, SAE1 antigen, MDA5 antigen, SSA / Ro52kD antigen, Ku antigen, PM-Scl 75 antigen, and PM-Scl100 antigen, respectively, and a fluorescently labeled secondary antibody solution; the JO-1 antigen comprises antigen A and antigen B, wherein antigen A is a natural antigen and antigen B is a recombinant antigen; the mass ratio of antigen A to antigen B coated on the fluorescently encoded magnetic microspheres coated with JO-1 antigen is 2:

1.

2. The detection kit for autoimmune myositis according to claim 1, characterized in that, In the suspension, the coating ratio of JO-1 antigen to fluorescently encoded magnetic microspheres was: 10 μg~200 μg of antigen coated with 1×102 6 A magnetic fluorescently encoded microsphere.

3. The detection kit for autoimmune myositis according to claim 1, characterized in that, The amino acid sequences of antigen A and antigen B are identical, as shown in SEQ ID NO.

1.

4. The detection kit for autoimmune myositis according to claim 1, characterized in that, The fluorescently labeled secondary antibody is an anti-human IgG antibody, which is selected from at least one of goat anti-human IgG antibody or mouse anti-human IgG antibody.

5. The detection kit for autoimmune myositis according to claim 1, characterized in that, The fluorescent substance includes at least one of phycoerythrin, phycoerythrin-Cy7 complex dye, fluorescein isothiocyanate, polydioxin-chlorophyll-protein complex, and allophycocyanin.

6. The detection kit for autoimmune myositis according to claim 1, characterized in that, The kit also includes a secondary antibody diluent.

7. The detection kit for autoimmune myositis according to claim 6, characterized in that, The secondary antibody dilution solution includes phosphate buffer containing bovine serum albumin and an inhibitor.

8. The detection kit for autoimmune myositis according to claim 7, characterized in that, The blocking agent includes an active blocking agent and a passive blocking agent. The active blocking agent is selected from at least one of human anti-mouse antibody blocking agents, heterophile antibody blocking agents, and rheumatoid factor blocking agents. The passive blocking agent is selected from at least one of mouse IgG, sheep IgG, goat IgG, and bovine IgG.

9. The detection kit for autoimmune myositis according to any one of claims 1 to 8, characterized in that, The kit also includes a sample diluent; the sample diluent includes at least one of phosphate buffer containing protein-containing serum and Tris buffer.